The Bismuth–Corlette classification system provides an anatomic description ... They often manifest as a concentric thickening of the bile duct, coupled with infiltration of the periductal ...

TransThera Sciences Nanjing, Inc. (the "TransThera") announced the poster presentation at the 2024 European Society For Medical Oncology (ESMO) Asia Congress to discuss the clinical study of ...

On November 20, 2024, the U.S. Food and Drug Administration granted accelerated approval to the drug zanidatamab (Ziihera ®) to treat advanced and metastatic bile duct cancer (cholangiocarcinoma) and ...

Biliary tract cancers encompass an estimated 3% of all gastrointestinal cancers and have a limited survival rate. 3 These types of cancers include intrahepatic cholangiocarcinoma, extrahepatic ...

Zanidatamab, a bispecific antibody, is indicated for previously treated unresectable or metastatic bile duct or gallbladder ...

FGFR2 gene fusion is observed in approximately 14% of intrahepatic cholangiocarcinoma, which accounts for 15%-30% of all biliary tract cancers, according to Eisai, but drug options are limited.

The FDA approved a companion diagnostic to identify patients with biliary tract cancer eligible for treatment with ...

Revolutionizing biliary obstruction care, EUS & ERCP lead the way with insights from the 2024 American Society for ...

Biliary tract disease describes any disease that ... secondary sclerosing cholangitis and biliary atresia. Intrahepatic cholangiocarcinoma (ICC) remains poorly characterised in Chinese patients.

FGFR2 gene fusions or rearrangements are observed in approximately 5-14% of intrahepatic cholangiocarcinoma, which accounts for 15-30% of biliary tract cancers.(5),(6),(7) FGFR genetic aberrations ...

Cholangiocarcinoma arises from the bile ducts and is the most common primary malignancy of the biliary tree. Cholangiocarcinoma is classified according to its growth pattern: mass-forming ...